Codexis, Inc. (CDXS) Stock Price & Analysis
Codexis, Inc. (CDXS) fell 25.63% to USD 1.48 as of July 25, 2026 at 09:06 UTC, according to Nexqual real-time market data.
CDXS last closed at USD 1.99; the session ranged USD 1.44–1.57 on volume of 10,350,039 shares. Market capitalization is $134.53M, with a 52-week range of USD 0.96–3.87 (NMS). Source: Nexqual, July 25, 2026 at 09:06 UTC.
Key Statistics (as of July 25, 2026 at 09:06 UTC)
| Price | USD 1.48 |
|---|---|
| Change | ▼ 25.63% (down) |
| Previous Close | USD 1.99 |
| Open | USD 1.49 |
| Day Range | USD 1.44 – 1.57 |
| 52-Week Range | USD 0.96 – 3.87 |
| Volume | 10,350,039 shares |
| Market Cap | $134.53M |
| Exchange | NMS |
Technical Analysis (CDXS)
Nexqual's technical model rates CDXS "SELL" based on 3 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 09:06 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 22.3 (oversold) |
| vs SMA50 | Below (USD 2.43) |
| MACD | -0.15 (negative) |
Analyst Ratings (CDXS)
Wall Street analysts rate CDXS "None" based on 6 analysts, with a mean price target of USD 6.58 (range USD 2–11), per Nexqual as of July 25, 2026 at 09:06 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 6.58 |
| High Target | USD 11 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 5 / 2 / 0 |
Earnings (CDXS)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.12 |
| Revenue Estimate | $13.82M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.1 vs est -0.11 ▲ beat |
| 2025-12-31 | USD 0.14 vs est -0.04 ▲ beat |
| 2025-09-30 | USD -0.22 vs est -0.13 ▼ miss |
| 2025-06-30 | USD -0.16 vs est -0.15 ▼ miss |
Source: Nexqual, July 25, 2026 at 09:06 UTC.
Financials & Fundamentals (CDXS)
| Total Revenue | $78.09M |
|---|---|
| Revenue Growth (YoY) | +102.10% |
| Gross Margin | +23.83% |
| Operating Margin | -52.75% |
| Profit Margin | -40.97% |
| ROE | -68.90% |
| Debt / Equity | 168.62 |
| Current Ratio | 5.36 |
| Total Cash | $65.14M |
| Total Debt | $72.90M |
| Free Cash Flow | $-8.48M |
Source: Nexqual, July 25, 2026 at 09:06 UTC.
Financial Health Score (CDXS)
Nexqual rates Codexis, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 09:06 UTC.
| Growth | Strong — Revenue +19% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 24%, operating -53% |
| Balance Sheet | Weak — $65M cash vs $73M debt |
| Cash Flow | Weak — FCF negative: -$8M, burning cash |
| Efficiency | Critical — ROE -69%, ROA -12.5% |
Ownership (CDXS)
| Insider Ownership | +7.41% |
|---|---|
| Institutional Ownership | +82.41% |
| Shares Outstanding | 90.90M |
| Float | 73.46M |
| Short % of Float | +4.19% |
Source: Nexqual, July 25, 2026 at 09:06 UTC.
Leadership (CDXS)
Codexis, Inc. is led by Alison Moore (age 58), President, CEO & Director, per Nexqual as of July 25, 2026 at 09:06 UTC.
| President, CEO & Director | Alison Moore (age 58) |
|---|---|
| CFO & Chief Business Officer | Georgia L. Erbez (age 58) |
| Chief Scientific Officer | Stefan Lutz |
Major Backers & Investors (CDXS)
Notable institutional backers of Codexis, Inc. include Aberdeen Group plc, Opaleye Management Inc., abrdn Healthcare Investors, according to Nexqual as of July 25, 2026 at 09:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Aberdeen Group plc | 9.55% |
| Opaleye Management Inc. | 7.46% |
| abrdn Healthcare Investors | 6.15% |
| Nantahala Capital Management, LLC | 4.54% |
| Millennium Management | 4.4% |
| Telemark Asset Management, LLC | 4.23% |
| Ameriprise Financial, Inc. | 3.74% |
| abrdn Life Sciences Investors | 3.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.46% |
| Vanguard Group | 7.91% |
Source: Nexqual, July 25, 2026 at 09:06 UTC.
From Codexis, Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
- The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
- It has a license agreement with Aldevron LLC and Pfizer Inc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDNA | CareDx, Inc. | USD 37.14 | ▼ 1.69% |
| FATE | Fate Therapeutics, Inc. | USD 2.41 | ▼ 6.59% |
| VCYT | Veracyte, Inc. | USD 56.61 | ▼ 2.41% |
| PSNL | Personalis, Inc. | USD 11.78 | ▼ 5.53% |
| CLLS | Cellectis S.A. | USD 2.84 | ▲ 1.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:06 UTC. This page is informational and not investment advice.